Evidence-based prescribing: Combining network meta-analysis with multicriteria decision analysis to choose among multiple drugs

Circulation: Cardiovascular Quality and Outcomes

Volumn 7, Issue 5, 2014, Pages 787-792

  Naci, Huseyin ^a,b   Van Valkenhoef, Gert ^c   Higgins, Julian P T ^d,e   Fleurence, Rachael ^f   Ades, A E ^d  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^b HARVARD PILGRIM HEALTH CARE INSTITUTE   (United States)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e UNIVERSITY OF YORK   (United Kingdom)

^f Outcomes Research Institute   (United States)

Author keywords

Cardiovascular agents; Cardiovascular diseases; Coronary disease; Decision making shared; Evidence based medicine; Hydroxymethylglutaryl CoA reductase inhibitors

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRESCRIPTION DRUG;

ANALYTICAL RESEARCH; CLINICAL DECISION MAKING; CLINICAL PRACTICE; DECISION SUPPORT SYSTEM; DRUG CHOICE; EVIDENCE BASED MEDICINE; EVIDENCE BASED PRACTICE; HUMAN; META ANALYSIS (TOPIC); MULTIPLE CRITERIA DECISION ANALYSIS; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; CARDIOVASCULAR DISEASES; CLINICAL TRIAL (TOPIC); DECISION MAKING; META ANALYSIS; PERSONALIZED MEDICINE; PROCEDURES; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DECISION MAKING; EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRACTICE PATTERNS, PHYSICIANS'; PRECISION MEDICINE; RISK ASSESSMENT;

EID: 84925595160     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.114.000825     Document Type: Review

References (45)

1. Ely JW, Osheroff JA, Gorman PN, Ebell MH, Chambliss ML, Pifer EA, Stavri PZ. A taxonomy of generic clinical questions: classification study. BMJ. 2000;321:429-432
2. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ. 1996;312:71-72
3. Naci H, Cylus J, Vandoros S, Sato A, Perampaladas K. Raising the bar for market authorisation of new drugs. BMJ. 2012;345
4. Sorenson C, Naci H, Cylus J, Mossialos E. Evidence of comparative efficacy should have a formal role in European drug approvals. BMJ. 2011;343:d4849
5. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005;331:897-900
6. Mills EJ, Thorlund K, Ioannidis JP. Demystifying trial networks and network meta-analysis. BMJ. 2013;346:f2914
7. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, de Craen AJ, Knopp RH, Nakamura H, Ridker P, van Domburg R, Deckers JW. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376
8. Cholesterol Treatment Trialists (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278
9. Cholesterol Treatment Trialists (CTT) Collaborators. Efficacy and safety of more intensive lowering of LDL cholesterol: a metaanalysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-1681
10. Cholesterol Treatment Trialists (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581-90
11. Silva M, Matthews ML, Jarvis C, Nolan NM, Belliveau P, Malloy M, Gandhi P. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther. 2007;29:253-260
12. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin-related adverse events: a meta-analysis. Clin Ther. 2006;28:26-35
13. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. 2008;52:1769-1781
14. Mills EJ, Wu P, Chong G, Ghement I, Singh S, Akl EA, Eyawo O, Guyatt G, Berwanger O, Briel M. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM. 2011;104:109-124
15. Zhou Z, Rahme E, Pilote L. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am Heart J. 2006;151:273-281
16. Ribeiro RA, Ziegelmann PK, Duncan BB, Stella SF, da Costa Vieira JL, Restelatto LM, Moriguchi EH, Polanczyk CA. Impact of statin dose on major cardiovascular events: a mixed treatment comparison meta-analysis involving more than 175,000 patients. Int J Cardiol. 2013;166:431-439
17. Alberton M, Wu P, Druyts E, Briel M, Mills EJ. Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis. QJM. 2012;105:145-157
18. Aitken M, Berndt ER, Cutler DM. Prescription drug spending trends in the United States: looking beyond the turning point. Health Aff (Millwood). 2009;28:w151-w160
19. Associated Press. Lipitor becomes the world's top-selling drug. 2011; http://www.crainsnewyork.com/article/20111228/HEALTH CARE/111229902. Accessed February 13, 2013
20. Naci H, Brugts J, Fleurence R, Ades AE. Comparative Efficacy and Safety of Statins: A Systematic Review and Mixed Treatment Comparison-Final Protocol. 2009. www2.lse.ac.uk/LSEHealthAndSocialCare/pdf/ HNaciProtocol.pdf. Accessed June 20, 2014
21. Naci H, Brugts JJ, Fleurence R, Ades AE. Dose-comparative effects of different statins on serum lipid levels: a network meta-analysis of 256,827 individuals in 181 randomized controlled trials. Eur J Prev Cardiol. 2013;20:658-670
22. Naci H, Brugts J, Fleurence R, Tsoi B, Toor H, Ades AE. Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials. Eur J Prev Cardiol. 2013;20:671-678
23. Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes. 2013;6:390-399
24. Naci H, Brugts JJ, Fleurence R, Ades AE. Comparative effects of statins on major cerebrovascular events: a multiple-treatments metaanalysis of placebo-controlled and active-comparator trials. QJM. 2013;106:299-306
25. Tervonen T, van Valkenhoef G, Buskens E, Hillege HL, Postmus D. A stochastic multicriteria model for evidence-based decision making in drug benefit-risk analysis. Stat Med. 2011;30:1419-1428
26. Thokala P, Duenas A. Multiple criteria decision analysis for health technology assessment. Value Health. 2012;15:1172-1181
27. Belton V, Stewart T. Multiple Criteria Decision Analysis-an Integrated Approach. Dordrecht: Kluwer Academic Publishers; 2001
28. Keeney RL, Raiffa H. Decisions With Multiple Objectives: Preferences and Value Tradeoffs. New York: Wiley; 1976
29. Tervonen T, Figueira J. A survey on stochastic multicriteria acceptability analysis methods. J Multi-Crit Decis Anal. 2008;15:1-14
30. van Valkenhoef G, Tervonen T, Zhao J, de Brock B, Hillege HL, Postmus D. Multicriteria benefit-risk assessment using network meta-analysis. J Clin Epidemiol. 2012;65:394-403
31. Finegold JA, Manisty CH, Goldacre B, Barron AJ, Francis DP. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prev Cardiol. 2014;21:464-474
32. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 suppl 2):S1-S45
33. Czarny MJ, Martin SS, Kohli P, Metkus T, Blumenthal RS. Nonfatal outcomes in the primary prevention of atherosclerotic cardiovascular disease: is all-cause mortality really all that matters? Circ Cardiovasc Qual Outcomes. 2014;7:481-485
34. Caldwell DM, Welton NJ, Dias S, Ades AE. Selecting the best scale for measuring treatment effect in a network meta-analysis: a case study in childhood nocturnal enuresis. Res Synth Meth. 2012;3:126-141
35. Tervonen T, van Valkenhoef G, Basturk N, Postmus D. Hit-And-Run enables efficient weight generation for simulation-based multiple criteria decision analysis. Eur J Oper Res. 2013;224:552-559
36. Chewning B, Bylund CL, Shah B, Arora NK, Gueguen JA, Makoul G. Patient preferences for shared decisions: a systematic review. Patient Educ Couns. 2012;86:9-18
37. Drug and Therapeutics Bulletin. An introduction to patient decision aids. BMJ 2013;347:f4147
38. O'Connor AM, Bennett CL, Stacey D, Barry M, Col NF, Eden KB, Entwistle VA, Fiset V, Holmes-Rovner M, Khangura S. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2009;3
39. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23:3105-3124
40. Dias S, Sutton AJ, Ades AE, Welton NJ. A generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013;33:607-617
41. Mills EJ, Ioannidis JP, Thorlund K, Schünemann HJ, Puhan MA, Guyatt GH. How to use an article reporting a multiple treatment comparison meta-analysis. JAMA. 2012;308:1246-1253
42. Jansen JP, Naci H. Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Med. 2013;11:159
43. Ioannidis JP. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA. 1998;279:281-286
44. Mossialos E, Mrazek M, Walley T. Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality. Maidenhead: Open University Press; 2004
45. Ioannidis JP, Naci H. How good is "Evidence" from clinical studies of drug effects and why might such evidence fail in the prediction of clinical utility of drugs? Ann Rev Pharmacol Toxicol. 2014;55.